Form 4: Stoke Therapeutics COO Huw M. Nash Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Huw M. Nash, COO & CBO of Stoke Therapeutics, exercised stock options and sold 50,000 shares of common stock on May 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 20, 2024, Huw M. Nash, the COO & CBO of Stoke Therapeutics, exercised a stock option to purchase 50,000 shares of common stock at a price of $0.40 per share.
- Simultaneously, Nash sold 50,000 shares of Stoke Therapeutics' common stock at a weighted average price of $15.39 per share.
- The sales were executed under a Rule 10b5-1 trading plan adopted on December 29, 2023.
- Following these transactions, Nash directly owns 0 shares of Stoke Therapeutics.
- Nash has granted a Limited Power of Attorney to Edward M. Kaye, Jonathan Allan, and Thomas Leggett to execute Forms 3, 4, and 5 on his behalf.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing insider trading activity. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Executives often receive stock options as part of their compensation and may sell shares for personal financial management.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
- Companies like Amgen, Biogen, and Vertex Pharmaceuticals also see regular Form 4 filings from their executives.
- The use of 10b5-1 trading plans is a standard practice to avoid accusations of illegal insider trading, allowing insiders to sell shares at predetermined times and prices.
Stakeholder Impact
- The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about opportunistic trading.
- The transactions have no immediate impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2023-12-29 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-05-14 | Date of Limited Power of Attorney execution |
| 2024-05-20 | Date of stock option exercise and share sale |
| 2024-05-22 | Date of Form 4 signature |
| 2026-02-11 | Expiration date of stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.